Department of Pharmaceutical Sciences and Natural Products, Central University of Punjab, Ghudda, Bathinda 151401, India.
Anticancer Agents Med Chem. 2022;22(17):2956-2984. doi: 10.2174/1871520622666220501162351.
Collagen is the most important structural protein and also the main component of the extra-cellular matrix (ECM). It plays a role in tumor progression. Collagen can be regulated by altering its biosynthesis pathway through various signaling pathways, receptors, and genes. The activity of cancer cells can also be regulated by other ECM components like metalloproteinases, hyaluronic acid, fibronectin, and so on. Hypoxia is also one of the conditions that lead to cancer progression by stimulating the expression of procollagen lysine as a collagen crosslinker, which increases the size of collagen fibres promoting cancer spread. The collagen content in cancerous cells leads to resistance to chemotherapy. So, to reduce this resistance, some collagen-regulating therapies are introduced, including inhibiting its biosynthesis, disturbing cancer cell signaling pathway, mediating ECM components, and directly utilizing collagenase. This study is an effort to compile the strategies reported to control the collagen level and different collagen inhibitors reported so far. More research is needed in this area. Growing understanding of collagen's structural features and its role in cancer progression will aid in the advancement of newer chemotherapies.
胶原蛋白是最重要的结构蛋白，也是细胞外基质（ECM）的主要成分。它在肿瘤进展中起作用。胶原蛋白可以通过改变其生物合成途径，通过各种信号通路、受体和基因进行调节。癌细胞的活性也可以通过其他 ECM 成分如金属蛋白酶、透明质酸、纤维连接蛋白等来调节。缺氧也是通过刺激作为胶原蛋白交联剂的脯氨酸赖氨酸前胶原的表达，增加促进癌症扩散的胶原蛋白纤维的大小，导致癌症进展的条件之一。癌细胞中的胶原蛋白含量导致对化疗的耐药性。因此，为了降低这种耐药性，引入了一些胶原蛋白调节疗法，包括抑制其生物合成、干扰癌细胞信号通路、调节 ECM 成分以及直接利用胶原酶。本研究旨在编译迄今为止报道的控制胶原蛋白水平和不同胶原蛋白抑制剂的策略。该领域需要更多的研究。对胶原蛋白结构特征及其在癌症进展中的作用的深入了解将有助于推进新型化疗药物的研发。
